Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals AB submitted a Phase I Clinical Trial Application in the EU for SR122, a dual GalNAc-conjugated siRNA therapy for dyslipidemia, including severe hypertriglyceridemia and mixed dyslipidemia. SR122 is designed to simultaneously target ApoC3 and PCSK9, addressing triglyceride-rich lipoproteins and LDL-C. The randomized, placebo-controlled Phase I study will assess subcutaneous SR122 for safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants. The filing follows Ribo's progress with Phase II studies of RBD5044 in Europe and China; Ribo describes RBD5044 as its core lipid asset and the world's second-most advanced ApoC3-targeting siRNA.